773 related articles for article (PubMed ID: 16963040)
1. Ovarian stimulation with daily late follicular phase administration of low-dose human chorionic gonadotropin for in vitro fertilization: a prospective, randomized trial.
Serafini P; Yadid I; Motta EL; Alegretti JR; Fioravanti J; Coslovsky M
Fertil Steril; 2006 Oct; 86(4):830-8. PubMed ID: 16963040
[TBL] [Abstract][Full Text] [Related]
2. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
[TBL] [Abstract][Full Text] [Related]
3. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
Cavagna M; Maldonado LG; de Souza Bonetti TC; de Almeida Ferreira Braga DP; Iaconelli A; Borges E
Fertil Steril; 2010 Jun; 94(1):167-72. PubMed ID: 19342035
[TBL] [Abstract][Full Text] [Related]
4. Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization.
Schmidt DW; Maier DB; Nulsen JC; Benadiva CA
Fertil Steril; 2004 Oct; 82(4):841-6. PubMed ID: 15482757
[TBL] [Abstract][Full Text] [Related]
5. Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders.
Berkkanoglu M; Isikoglu M; Aydin D; Ozgur K
Fertil Steril; 2007 Sep; 88(3):665-9. PubMed ID: 17292895
[TBL] [Abstract][Full Text] [Related]
6. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
Papanikolaou EG; Pozzobon C; Kolibianakis EM; Camus M; Tournaye H; Fatemi HM; Van Steirteghem A; Devroey P
Fertil Steril; 2006 Jan; 85(1):112-20. PubMed ID: 16412740
[TBL] [Abstract][Full Text] [Related]
7. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
[TBL] [Abstract][Full Text] [Related]
8. Ovarian stimulation protocols based on follicle-stimulating hormone glycosylation pattern: impact on oocyte quality and clinical outcome.
Selman H; Pacchiarotti A; El-Danasouri I
Fertil Steril; 2010 Oct; 94(5):1782-6. PubMed ID: 19939369
[TBL] [Abstract][Full Text] [Related]
9. A comparison of 3-day and daily follicle-stimulating hormone injections on stimulation days 1-6 in women undergoing controlled ovarian hyperstimulation.
Scholtes MC; Schnittert B; van Hoogstraten D; Verhoeven HC; Zrener A; Warne DW
Fertil Steril; 2004 Apr; 81(4):996-1001. PubMed ID: 15066454
[TBL] [Abstract][Full Text] [Related]
10. Comparison of serum and follicular fluid hormone levels with recombinant and urinary human chorionic gonadotropin during in vitro fertilization.
Kovacs P; Kovats T; Bernard A; Zadori J; Szmatona G; Kaali SG
Fertil Steril; 2008 Dec; 90(6):2133-7. PubMed ID: 18177866
[TBL] [Abstract][Full Text] [Related]
11. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.
Humaidan P; Ejdrup Bredkjaer H; Westergaard LG; Yding Andersen C
Fertil Steril; 2010 Feb; 93(3):847-54. PubMed ID: 19200959
[TBL] [Abstract][Full Text] [Related]
12. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates.
Acevedo B; Gomez-Palomares JL; Ricciarelli E; Hernández ER
Fertil Steril; 2006 Dec; 86(6):1682-7. PubMed ID: 17074344
[TBL] [Abstract][Full Text] [Related]
13. Can 200 IU of hCG replace recombinant FSH in the late follicular phase in a GnRH-antagonist cycle? A pilot study.
Blockeel C; De Vos M; Verpoest W; Stoop D; Haentjens P; Devroey P
Hum Reprod; 2009 Nov; 24(11):2910-6. PubMed ID: 19617207
[TBL] [Abstract][Full Text] [Related]
14. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.
Barrenetxea G; Agirregoikoa JA; Jiménez MR; de Larruzea AL; Ganzabal T; Carbonero K
Fertil Steril; 2008 Mar; 89(3):546-53. PubMed ID: 17531989
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation.
Filicori M; Cognigni GE; Gamberini E; Parmegiani L; Troilo E; Roset B
Fertil Steril; 2005 Aug; 84(2):394-401. PubMed ID: 16084880
[TBL] [Abstract][Full Text] [Related]
16. Diminished intrafollicular estradiol levels in in vitro fertilization cycles from women with reduced ovarian response to recombinant human follicle-stimulating hormone.
Foong SC; Abbott DH; Lesnick TG; Session DR; Walker DL; Dumesic DA
Fertil Steril; 2005 May; 83(5):1377-83. PubMed ID: 15866572
[TBL] [Abstract][Full Text] [Related]
17. Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study.
European Recombinant LH Study Group
J Clin Endocrinol Metab; 2001 Jun; 86(6):2607-18. PubMed ID: 11397861
[TBL] [Abstract][Full Text] [Related]
18. Luteinizing hormone concentrations after gonadotropin-releasing hormone antagonist administration do not influence pregnancy rates in in vitro fertilization-embryo transfer.
Merviel P; Antoine JM; Mathieu E; Millot F; Mandelbaum J; Uzan S
Fertil Steril; 2004 Jul; 82(1):119-25. PubMed ID: 15236999
[TBL] [Abstract][Full Text] [Related]
19. Substituting human chorionic gonadotropin by gonadotropin-releasing hormone agonist to trigger final follicular maturation, during controlled ovarian hyperstimulation, results in less systemic inflammation.
Orvieto R; Zagatsky I; Yulzari-Roll V; La Marca A; Fisch B
Gynecol Endocrinol; 2006 Aug; 22(8):437-40. PubMed ID: 17012105
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of highly purified urinary FSH versus recombinant FSH in volunteers undergoing controlled ovarian stimulation for in vitro fertilization: a randomized, multicenter, investigator-blind trial.
Baker VL; Fujimoto VY; Kettel LM; Adamson GD; Hoehler F; Jones CE; Soules MR
Fertil Steril; 2009 Apr; 91(4):1005-11. PubMed ID: 18367182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
